Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant humanized antibody expressed in CHO binding to human MS4A1/CD20. Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets mature B lymphocytes and hence is an immunosuppressive drug candidate. It had reached Phase III clinical trials for rheumatoid arthritis and lupus erythematosus, and Phase II for multiple scleros is and hematological cancer.
Target
MS4A1/CD20
Type
IgG1
Immunogen
The details of the immunogen for this antibody are not available.
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in ELISA, IP, FC, FuncS, Neut, IF, ICC and most other immunological methods.
CAS
637334-45-3
Molecular Weight
148 kDa
Purity
>95%, by SDS-PAGE with silver staining, under reducing conditions.
Size
1mg
Storage
Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.
BACKGROUND
Introduction
Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets mature B lymphocytes and hence is animmunosuppressive drug candidate.
Antigen Description
This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases.